Advertisement

Advances in the Diagnosis and Treatment of GERD: New Tricks for an Old Disease

  • Rishi D. Naik
  • Lauren Evers
  • Michael F. VaeziEmail author
Esophagus (PG Iyer, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Esophagus

Abstract

Purpose of review

Gastroesophageal reflux disease (GERD) is a common diagnosis encountered by both primary care providers and specialists, but despite its prevalence, there are limitations in the current diagnostic tests for GERD. Once an accurate diagnosis is made, treatment options can be offered, and this field continues to burgeon with options. In this review, we seek to review the recent advances in GERD diagnostics and subsequent treatment options.

Recent findings

Novel impedance markers and novel techniques (mucosal impedance testing, salivary pepsin, high-resolution manometry, and narrow-band imaging) have shown promise in diagnosing GERD. Advances in medical therapy, including potassium-competitive acid blockers and bile acid sequestrants, along with advances in invasive therapy (transoral incisionless fundoplication, endoscopic radiofrequency, electrical stimulation of the LES, and magnetic sphincter augmentation) have provided additional options for therapy for GERD beyond PPI and anti-reflux surgery.

Summary

Novel impedance markers and techniques will provide further clarity on mucosal integrity and the barrier function allowing improved diagnostic accuracy of GERD. Improvements in medical and invasive therapy will expand GERD therapy.

Keywords

GERD Diagnostics Treatment Manometry Motility Mucosal impedance testing 

Notes

Author contributions

Authored first draft (RDN, LE), critical revisions (all), approved final draft (all).

Compliance with Ethical Standards

Conflict of Interest

Rishi Naik declares that he has no conflict of interest. Lauren Evers declares that she has no conflict of interest. Michael Vaezi declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Financial and Competing Interest Disclosure

Competing interest:

Vanderbilt and Diversatek co-own the patent on MIT technology discussed in this review.

No writing assistance was utilized in the production of this manuscript.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871–80.CrossRefGoogle Scholar
  2. 2.
    Shaheen NJ, Hansen RA, Morgan DR, Gangarosa LM, Ringel Y, Thiny MT, et al. The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol. 2006;101(9):2128–38.CrossRefGoogle Scholar
  3. 3.
    Castell DO, Murray JA, Tutuian R, Orlando RC, Arnold R. Review article: the pathophysiology of gastro-oesophageal reflux disease—oesophageal manifestations. Aliment Pharmacol Ther. 2004;20(Suppl 9):14–25.CrossRefGoogle Scholar
  4. 4.
    de Bortoli N, Ottonello A, Zerbib F, Sifrim D, Gyawali CP, Savarino E. Between GERD and NERD: the relevance of weakly acidic reflux. Ann N Y Acad Sci. 2016;1380(1):218–29.CrossRefGoogle Scholar
  5. 5.
    Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108(3):308–28 quiz 329.Google Scholar
  6. 6.
    Vaezi MF, Katzka D, Zerbib F. Extraesophageal symptoms and diseases attributed to GERD: where is the pendulum swinging now? Clin Gastroenterol Hepatol. 2018;16(7):1018–29.CrossRefGoogle Scholar
  7. 7.
    Koufman JA, Aviv JE, Casiano RR, Shaw GY. Laryngopharyngeal reflux: position statement of the committee on speech, voice, and swallowing disorders of the American Academy of Otolaryngology-Head and Neck Surgery. Otolaryngol Head Neck Surg. 2002;127(1):32–5.CrossRefGoogle Scholar
  8. 8.
    Kahrilas PJ, Boeckxstaens G, Smout AJ. Management of the patient with incomplete response to PPI therapy. Best Pract Res Clin Gastroenterol. 2013;27(3):401–14.CrossRefGoogle Scholar
  9. 9.
    Dent J. Review article: from 1906 to 2006—a century of major evolution of understanding of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2006;24(9):1269–81.CrossRefGoogle Scholar
  10. 10.
    Herregods TV, Bredenoord AJ, Smout AJ. Pathophysiology of gastroesophageal reflux disease: new understanding in a new era. Neurogastroenterol Motil. 2015;27(9):1202–13.CrossRefGoogle Scholar
  11. 11.
    Dent J, Vakil N, Jones R, Bytzer P, Schoning U, Halling K, et al. Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study. Gut. 2010;59(6):714–21.CrossRefGoogle Scholar
  12. 12.
    Bolier EA, Kessing BF, Smout AJ, Bredenoord AJ. Systematic review: questionnaires for assessment of gastroesophageal reflux disease. Dis Esophagus. 2015;28(2):105–20.CrossRefGoogle Scholar
  13. 13.
    Savarino E, Zentilin P, Savarino V. NERD: an umbrella term including heterogeneous subpopulations. Nat Rev Gastroenterol Hepatol. 2013;10(6):371–80.CrossRefGoogle Scholar
  14. 14.
    Poh CH, Gasiorowska A, Navarro-Rodriguez T, Willis MR, Hargadon D, Noelck N, et al. Upper GI tract findings in patients with heartburn in whom proton pump inhibitor treatment failed versus those not receiving antireflux treatment. Gastrointest Endosc. 2010;71(1):28–34.CrossRefGoogle Scholar
  15. 15.
    Akdamar K, Ertan A, Agrawal NM, McMahon FG, Ryan J. Upper gastrointestinal endoscopy in normal asymptomatic volunteers. Gastrointest Endosc. 1986;32(2):78–80.CrossRefGoogle Scholar
  16. 16.
    Takashima T, Iwakiri R, Sakata Y, Yamaguchi D, Tsuruoka N, Akutagawa K, et al. Endoscopic reflux esophagitis and Helicobacter pylori infection in young healthy Japanese volunteers. Digestion. 2012;86(1):55–8.CrossRefGoogle Scholar
  17. 17.
    Zagari RM, Fuccio L, Wallander MA, Johansson S, Fiocca R, Casanova S, et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett’s oesophagus in the general population: the Loiano-Monghidoro study. Gut. 2008;57(10):1354–9.CrossRefGoogle Scholar
  18. 18.
    Sifrim D, Castell D, Dent J, Kahrilas PJ. Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut. 2004;53(7):1024–31.CrossRefGoogle Scholar
  19. 19.
    Savarino E, Marabotto E, Zentilin P, Frazzoni M, Sammito G, Bonfanti D, et al. The added value of impedance-pH monitoring to Rome III criteria in distinguishing functional heartburn from non-erosive reflux disease. Dig Liver Dis. 2011;43(7):542–7.CrossRefGoogle Scholar
  20. 20.
    Zerbib F, Roman S, Ropert A, des Varannes SB, Pouderoux P, Chaput U, et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol. 2006;101(9):1956–63.CrossRefGoogle Scholar
  21. 21.
    Frazzoni M, de Bortoli N, Frazzoni L, Furnari M, Martinucci I, Tolone S, et al. Impairment of chemical clearance and mucosal integrity distinguishes hypersensitive esophagus from functional heartburn. J Gastroenterol. 2017;52(4):444–51.CrossRefGoogle Scholar
  22. 22.
    de Bortoli N, Martinucci I, Savarino E, Tutuian R, Frazzoni M, Piaggi P, et al. Association between baseline impedance values and response proton pump inhibitors in patients with heartburn. Clin Gastroenterol Hepatol. 2015;13(6):1082–8 e1081.Google Scholar
  23. 23.
    Frazzoni M, Savarino E, de Bortoli N, Martinucci I, Furnari M, Frazzoni L, et al. Analyses of the post-reflux swallow-induced peristaltic wave index and nocturnal baseline impedance parameters increase the diagnostic yield of impedance-pH monitoring of patients with reflux disease. Clin Gastroenterol Hepatol. 2016;14(1):40–6.CrossRefGoogle Scholar
  24. 24.
    Martinucci I, Savarino EV, Pandolfino JE, Russo S, Bellini M, Tolone S, et al. Vigor of peristalsis during multiple rapid swallows is inversely correlated with acid exposure time in patients with NERD. Neurogastroenterol Motil. 2016;28(2):243–50.CrossRefGoogle Scholar
  25. 25.
    • Frazzoni L, Frazzoni M, de Bortoli N, et al. Postreflux swallow-induced peristaltic wave index and nocturnal baseline impedance can link PPI-responsive heartburn to reflux better than acid exposure time. Neurogastroenterol Motil. 2017;29(11). Important study on the role of PSPW.Google Scholar
  26. 26.
    Caviglia R, Ribolsi M, Maggiano N, Gabbrielli AM, Emerenziani S, Guarino MPL, et al. Dilated intercellular spaces of esophageal epithelium in nonerosive reflux disease patients with physiological esophageal acid exposure. Am J Gastroenterol. 2005;100(3):543–8.CrossRefGoogle Scholar
  27. 27.
    Farre R, Blondeau K, Clement D, Vicario M, Cardozo L, Vieth M, et al. Evaluation of oesophageal mucosa integrity by the intraluminal impedance technique. Gut. 2011;60(7):885–92.CrossRefGoogle Scholar
  28. 28.
    Kessing BF, Bredenoord AJ, Weijenborg PW, Hemmink GJ, Loots CM, Smout AJ. Esophageal acid exposure decreases intraluminal baseline impedance levels. Am J Gastroenterol. 2011;106(12):2093–7.CrossRefGoogle Scholar
  29. 29.
    Kandulski A, Weigt J, Caro C, Jechorek D, Wex T, Malfertheiner P. Esophageal intraluminal baseline impedance differentiates gastroesophageal reflux disease from functional heartburn. Clin Gastroenterol Hepatol. 2015;13(6):1075–81.CrossRefGoogle Scholar
  30. 30.
    Zhong C, Duan L, Wang K, Xu Z, Ge Y, Yang C, et al. Esophageal intraluminal baseline impedance is associated with severity of acid reflux and epithelial structural abnormalities in patients with gastroesophageal reflux disease. J Gastroenterol. 2013;48(5):601–10.CrossRefGoogle Scholar
  31. 31.
    Woodland P, Al-Zinaty M, Yazaki E, Sifrim D. In vivo evaluation of acid-induced changes in oesophageal mucosa integrity and sensitivity in non-erosive reflux disease. Gut. 2013;62(9):1256–61.CrossRefGoogle Scholar
  32. 32.
    Martinucci I, de Bortoli N, Savarino E, Piaggi P, Bellini M, Antonelli A, et al. Esophageal baseline impedance levels in patients with pathophysiological characteristics of functional heartburn. Neurogastroenterol Motil. 2014;26(4):546–55.CrossRefGoogle Scholar
  33. 33.
    Frazzoni M, de Bortoli N, Frazzoni L, et al. The added diagnostic value of postreflux swallow-induced peristaltic wave index and nocturnal baseline impedance in refractory reflux disease studied with on-therapy impedance-pH monitoring. Neurogastroenterol Motil. 2017;29(3).Google Scholar
  34. 34.
    Patel A, Wang D, Sainani N, Sayuk GS, Gyawali CP. Distal mean nocturnal baseline impedance on pH-impedance monitoring predicts reflux burden and symptomatic outcome in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2016;44(8):890–8.CrossRefGoogle Scholar
  35. 35.
    van Rhijn BD, Weijenborg PW, Verheij J, van den Bergh Weerman MA, Verseijden C, van den Wijngaard RMJGJ, et al. Proton pump inhibitors partially restore mucosal integrity in patients with proton pump inhibitor-responsive esophageal eosinophilia but not eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2014;12(11):1815–23 e1812.Google Scholar
  36. 36.
    Rinsma NF, Farre R, Bouvy ND, Masclee AA, Conchillo JM. The effect of endoscopic fundoplication and proton pump inhibitors on baseline impedance and heartburn severity in GERD patients. Neurogastroenterol Motil. 2015;27(2):220–8.CrossRefGoogle Scholar
  37. 37.
    Frazzoni L, Frazzoni M, de Bortoli N, et al. Critical appraisal of Rome IV criteria: hypersensitive esophagus does belong to gastroesophageal reflux disease spectrum. Ann Gastroenterol. 2018;31(1):1–7.Google Scholar
  38. 38.
    Saritas Yuksel E, Higginbotham T, Slaughter JC, Mabary J, Kavitt RT, Garrett CG, et al. Use of direct, endoscopic-guided measurements of mucosal impedance in diagnosis of gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2012;10(10):1110–6.CrossRefGoogle Scholar
  39. 39.
    Katzka DA, Ravi K, Geno DM, Smyrk TC, Iyer PG, Alexander JA, et al. Endoscopic mucosal impedance measurements correlate with eosinophilia and dilation of intercellular spaces in patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2015;13(7):1242–8 e1241.Google Scholar
  40. 40.
    Ates F, Yuksel ES, Higginbotham T, Slaughter JC, Mabary J, Kavitt RT, et al. Mucosal impedance discriminates GERD from non-GERD conditions. Gastroenterology. 2015;148(2):334–43.CrossRefGoogle Scholar
  41. 41.
    Choksi Y, Lal P, Slaughter JC, Sharda R, Parnell J, Higginbotham T, et al. Esophageal mucosal impedance patterns discriminate patients with eosinophilic esophagitis from patients with GERD. Clin Gastroenterol Hepatol. 2018;16(5):664–71 e661.Google Scholar
  42. 42.
    Barrett C, Choksi Y, Vaezi MF. Mucosal impedance: a new approach to diagnosing gastroesophageal reflux disease and eosinophilic esophagitis. Curr Gastroenterol Rep. 2018;20(7):33.CrossRefGoogle Scholar
  43. 43.
    Vaezi MF, Choksi Y. Mucosal impedance: a new way to diagnose reflux disease and how it could change your practice. Am J Gastroenterol. 2017;112(1):4–7.CrossRefGoogle Scholar
  44. 44.
    Bredenoord AJ, Weusten BL, Timmer R, Smout AJ. Intermittent spatial separation of diaphragm and lower esophageal sphincter favors acidic and weakly acidic reflux. Gastroenterology. 2006;130(2):334–40.CrossRefGoogle Scholar
  45. 45.
    • Gyawali CP, Kahrilas PJ, Savarino E, et al. Modern diagnosis of GERD: the Lyon consensus. Gut. 2018;67(7):1351–62. Excellent review of modern diagnostic tests for GERD.CrossRefGoogle Scholar
  46. 46.
    Nicodeme F, Pipa-Muniz M, Khanna K, Kahrilas PJ, Pandolfino JE. Quantifying esophagogastric junction contractility with a novel HRM topographic metric, the EGJ-contractile integral: normative values and preliminary evaluation in PPI non-responders. Neurogastroenterol Motil. 2014;26(3):353–60.CrossRefGoogle Scholar
  47. 47.
    Tolone S, De Bortoli N, Marabotto E, et al. Esophagogastric junction contractility for clinical assessment in patients with GERD: a real added value? Neurogastroenterol Motil. 2015;27(10):1423–31.CrossRefGoogle Scholar
  48. 48.
    Jasper D, Freitas-Queiroz N, Hollenstein M, et al. Prolonged measurement improves the assessment of the barrier function of the esophago-gastric junction by high-resolution manometry. Neurogastroenterol Motil. 2017;29(2).Google Scholar
  49. 49.
    Wang D, Xu H, Tang T, Wang J, Yu Y, Gyawali CP. Assessment of the esophagogastric junction (EGJ) using the EGJ contractile integral (EGJ-CI) following per-oral endoscopic myotomy (POEM) in achalasia. Rev Esp Enferm Dig. 2018;110.Google Scholar
  50. 50.
    Wang D, Patel A, Mello M, Shriver A, Gyawali CP. Esophagogastric junction contractile integral (EGJ-CI) quantifies changes in EGJ barrier function with surgical intervention. Neurogastroenterol Motil. 2016;28(5):639–46.CrossRefGoogle Scholar
  51. 51.
    Xie C, Wang J, Li Y, Tan N, Cui Y, Chen M, et al. Esophagogastric junction contractility integral reflect the anti-reflux barrier dysfunction in patients with gastroesophageal reflux disease. J Neurogastroenterol Motil. 2017;23(1):27–33.CrossRefGoogle Scholar
  52. 52.
    Potluri S, Friedenberg F, Parkman HP, Chang A, MacNeal R, Manus C, et al. Comparison of a salivary/sputum pepsin assay with 24-hour esophageal pH monitoring for detection of gastric reflux into the proximal esophagus, oropharynx, and lung. Dig Dis Sci. 2003;48(9):1813–7.CrossRefGoogle Scholar
  53. 53.
    Saritas Yuksel E, Hong SK, Strugala V, et al. Rapid salivary pepsin test: blinded assessment of test performance in gastroesophageal reflux disease. Laryngoscope. 2012;122(6):1312–6.CrossRefGoogle Scholar
  54. 54.
    Yadlapati R, Adkins C, Jaiyeola DM, Lidder AK, Gawron AJ, Tan BK, et al. Abilities of oropharyngeal pH tests and salivary pepsin analysis to discriminate between asymptomatic volunteers and subjects with symptoms of laryngeal irritation. Clin Gastroenterol Hepatol. 2016;14(4):535–42 e532.Google Scholar
  55. 55.
    Ocak E, Kubat G, Yorulmaz I. Immunoserologic pepsin detection in the saliva as a non-invasive rapid diagnostic test for laryngopharyngeal reflux. Balkan Med J. 2015;32(1):46–50.CrossRefGoogle Scholar
  56. 56.
    Fock KM, Teo EK, Ang TL, Tan JY, Law NM. The utility of narrow band imaging in improving the endoscopic diagnosis of gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2009;7(1):54–9.CrossRefGoogle Scholar
  57. 57.
    Arul P, Vinoth B, Alexander T, Phansalkar M, Padhi S. Correlation of narrow band imaging endoscopy and histopathology in the diagnosis of nonerosive reflux disease. Saudi J Gastroenterol. 2015;21(5):330–6.CrossRefGoogle Scholar
  58. 58.
    Tseng PH, Chen CC, Chiu HM, Liao WC, Wu MS, Lin JT, et al. Performance of narrow band imaging and magnification endoscopy in the prediction of therapeutic response in patients with gastroesophageal reflux disease. J Clin Gastroenterol. 2011;45(6):501–6.CrossRefGoogle Scholar
  59. 59.
    Hillman L, Yadlapati R, Thuluvath AJ, Berendsen MA, Pandolfino JE. A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease. Dis Esophagus. 2017;30(9):1–15.Google Scholar
  60. 60.
    •• Gyawali CP, Fass R. Management of gastroesophageal reflux disease. Gastroenterology. 2018;154(2):302–18. Updated guidelines on the management of GERD.CrossRefGoogle Scholar
  61. 61.
    Ashida K, Sakurai Y, Nishimura A, Kudou K, Hiramatsu N, Umegaki E, et al. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther. 2015;42(6):685–95.CrossRefGoogle Scholar
  62. 62.
    Iwakiri K, Sakurai Y, Shiino M, Okamoto H, Kudou K, Nishimura A, et al. A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis. Ther Adv Gastroenterol. 2017;10(6):439–51.CrossRefGoogle Scholar
  63. 63.
    Vaezi MF, Fass R, Vakil N, et al. 875-Iw-3718, a novel gastric-retentive bile acid sequestrant, improved heartburn and regurgitation symptoms in patients with persistent gerd despite ppi treatment: a double-blind, placebo-controlled study. Gastroenterology. 2018;154(6):S-174.CrossRefGoogle Scholar
  64. 64.
    Fass R, Cahn F, Scotti DJ, Gregory DA. Systematic review and meta-analysis of controlled and prospective cohort efficacy studies of endoscopic radiofrequency for treatment of gastroesophageal reflux disease. Surg Endosc. 2017;31(12):4865–82.CrossRefGoogle Scholar
  65. 65.
    Lipka S, Kumar A, Richter JE. No evidence for efficacy of radiofrequency ablation for treatment of gastroesophageal reflux disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2015;13(6):1058–67 e1051.Google Scholar
  66. 66.
    Huang X, Chen S, Zhao H, Zeng X, Lian J, Tseng Y, et al. Efficacy of transoral incisionless fundoplication (TIF) for the treatment of GERD: a systematic review with meta-analysis. Surg Endosc. 2017;31(3):1032–44.CrossRefGoogle Scholar
  67. 67.
    Richter JE, Kumar A, Lipka S, Miladinovic B, Velanovich V. Efficacy of laparoscopic Nissen fundoplication vs transoral incisionless fundoplication or proton pump inhibitors in patients with gastroesophageal reflux disease: a systematic review and network meta-analysis. Gastroenterology. 2018;154(5):1298–308 e1297.Google Scholar
  68. 68.
    Rodriguez L, Rodriguez P, Gomez B, et al. Long-term results of electrical stimulation of the lower esophageal sphincter for the treatment of gastroesophageal reflux disease. Endoscopy. 2013;45(8):595–604.CrossRefGoogle Scholar
  69. 69.
    Kappelle WF, Bredenoord AJ, Conchillo JM, et al. Electrical stimulation therapy of the lower oesophageal sphincter for refractory gastro-oesophageal reflux disease—interim results of an international multicentre trial. Aliment Pharmacol Ther. 2015;42(5):614–25.CrossRefGoogle Scholar
  70. 70.
    Ganz RA, Edmundowicz SA, Taiganides PA, Lipham JC, Smith CD, DeVault KR, et al. Long-term outcomes of patients receiving a magnetic sphincter augmentation device for gastroesophageal reflux. Clin Gastroenterol Hepatol. 2016;14(5):671–7.CrossRefGoogle Scholar
  71. 71.
    •• Bell RC, Lipham JC, Louie BE, et al. Laparoscopic magnetic sphincter augmentation versus double-dose proton pump inhibitors for management of moderate-to-severe regurgitation in GERD: a randomized controlled trial. Gastrointest Endosc. 2018. Recent RCT on the role of MSA in GERD management.Google Scholar
  72. 72.
    Sugano K. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. Ther Adv Gastroenterol. 2018;11:1756283X17745776.CrossRefGoogle Scholar
  73. 73.
    Kim SE, Soffer E. Electrical stimulation for gastroesophageal reflux disease: current state of the art. Clin Exp Gastroenterol. 2016;9:11–9.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Rishi D. Naik
    • 1
  • Lauren Evers
    • 1
  • Michael F. Vaezi
    • 1
    Email author
  1. 1.Division of Gastroenterology, Hepatology, and Nutrition, Center for Swallowing and Esophageal Disorders, Digestive Disease CenterVanderbilt University Medical CenterNashvilleUSA

Personalised recommendations